CereScan® Demos CereMetrix® at Society for Nuclear Medicine and Molecular Imaging Annual Conference

3D Graphics

Denver (June 19, 2017) – CereScan®, a leading provider of neuro-diagnostics solutions, presented the newest features, capabilities and use cases of its CereMetrix® platform during the Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Conference at the Colorado Convention Center last week. CereMetrix® is a patented, statistically-correlated, normative and scalable medical database designed to aid in the diagnosis and treatment of the human brain.

CereMetrix® will provide the healthcare community with the most robust resource on conditions like traumatic brain injury, toxic brain injury, Alzheimer’s Disease and other dementias, PTSD, bipolar disorder, ADHD, anxiety, autism and depression. It’s a brain focused medical analytics platform that may accelerate the accurate and effective diagnosis of complex brain-related disorders to improve treatment and outcomes for patients.

“We see SNMMI members as core stakeholders for CereMetrix® and wanted to engage them to both share our vision and get feedback on the solution. I’m happy to report that the response was overwhelmingly favorable and we now feel that we are innovating in the right direction,” said John Kelley Jr., Chairman and CEO of CereScan.

The key attributes of CereMetrix® include:

  • Unique, medical database for diagnosing complex brain-related disorders based on HD functional imagery and voxel level analysis
  • Provide a highly accurate, statistically valid standardized normative dataset for comparison and correlation of related symptomology
  • Proprietary software, scalable platform, with advanced intelligence and predicative analytics capabilities
  • Robust capabilities and easy to use
  • Accelerate accurate and effective diagnosis across the range of complex brain disorders
  • Enable appropriate diagnosis and treatment

 

About CereScan®
CereScan® combines state-of-the-art brain imaging technologies with a patient-centered model of care to provide the highest level of neuro-diagnostics available. CereScan® utilizes state-of-the-art gamma camera technology, new generation imaging software and a proprietary process to produce comprehensive medical reports including voxel level images of brain function and physiology. Our functional brain imaging technologies are the most sophisticated in the world today. Additional information about the company is available at https://cerescan.com.

CereScan® and CereMetrix® are registered trademark of CereHealth Corp.

CereScan Participates in Largest Brain Amyloid Scan Research Study

Alzheimer's IDEAS brain studyCereScan is now a registered amyloid positron emission tomography (PET) imaging site in the $100 million Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study (Ideas-Study.org). CereScan can offer Medicare-covered amyloid PET scans to study eligible Medicare patients who are referred by participating IDEAS dementia specialists (neurologists, psychiatrists and geriatric medicine physicians). The research study seeks to determine the clinical usefulness of PET imaging of brain amyloid deposits in the diagnosis of patients who are being evaluated for Alzheimer’s disease and dementia.

“Medicare will only cover these exams for seniors if done as part of clinical trial or data registry. Currently no private insurer covers amyloid PET scans for patients being evaluated for dementia or memory loss. I encourage local dementia specialists to review participation requirements, register for the trial and refer eligible patients to CereScan to get Medicare-covered amyloid PET scans that may better inform their care and future Alzheimer’s diagnosis and treatment,” said John Kelley, CereScan Chairman and Chief Executive Officer.

Diagnosing Alzheimer’s Disease is Complex

With no single test currently available, diagnosis is based on an individual’s history, physical examination and cognitive testing. Amyloid PET imaging represents a potential major advance in the assessment of people with cognitive impairment. The scan visualizes plaques present in the brain that are prime suspects in damaging and killing nerve cells in Alzheimer’s. Before amyloid PET, these plaques could only be detected by examining the brain at autopsy. The IDEAS study will follow Medicare beneficiaries to determine if amyloid PET scans may help physicians make more informed treatment decisions.

“There has never been a study of this scale to evaluate the clinical value of brain amyloid imaging in diagnosing and caring for those affected by Alzheimer’s. The dementia specialists and facilities that register for the IDEAS Study will play an essential role in engaging the nearly 19,000 individuals needed in the study and carrying out the amyloid PET scans,” said Maria Carrillo, PhD, Alzheimer’s Association chief science officer and IDEAS Study investigator.

How to Participate in the IDEAS Study

Patients cannot directly enroll in the IDEAS Study. IDEAS Study dementia specialists must enroll patients whose cases meet the study criteria and refer them to registered PET imaging facilities, such as CereScan for an amyloid PET scan. These scans will be performed and interpreted by a nuclear medicine physician or radiologist who is registered to take part in the IDEAS Study. Results will be provided to the ordering doctor for disclosure to the patient and to support further diagnostic decisions. Scan results and diagnosis will be captured for the study.

The IDEAS Study is sponsored by the American College of Radiology (ACR) and American College of Radiology Imaging Network (ACRIN), with funding and direction provided by the Alzheimer’s Association, the ACR and the manufacturers of the FDA-approved radiopharmaceuticals for amyloid imaging.

Step-by-step registration instructions are available for board-certified neurologists, psychiatrists and geriatric medicine physicians interested in enrolling eligible patients in the IDEAS Study.

Registered dementia specialists interested in referring enrolled patients to CereScan can call (866) 722-4806 or write to sstrauss@cerescan.com.

CereScan’s Ability to Accurately Show Presence of Mild to Moderate Traumatic Brain Injuries Provides Value in Legal Process

While traditional approaches to traumatic brain injury detection can be inconclusive, including MRI and CT scans, another technology is gaining notoriety with legal and medical professionals.

MRI vs CereSCanReferred by the Centers for Disease Control and Prevention as a “silent epidemic,” traumatic brain injury (TBI) affects millions every year, but this invisible injury is often difficult to diagnose.  Traditional imaging results are generally inconclusive for people with concussions – or mild TBI – as the damage associated with the injury often impacts cellular function and MRI and CT scans only analyze the structure of the brain.

However, an advance technology utilized by CereLaw called qSPECT (quantitative Single Photon Emission Computed Tomography) is aiding attorneys and medical providers.  The qSPECT process establishes the existence of mild- to moderate-TBI and its effects through SPECT imaging, advanced imaging software, detailed medical history and clinical assessments. SPECT imaging measures and analyzes blood flow levels throughout the brain to pinpoint the exact area impacted by the injury.

Lead by Brett Green, Esq. the CereLaw team is increasing awareness of TBI detection technologies available to attorneys through industry conferences such as the 2016 BIACAL Med-Legal Conference on Nov. 18 – 19 in Napa, California, and the Texas Trial Lawyers Association’s Annual Meeting on Dec. 8 – 9 in Dallas, Texas.

“Industry conferences are a great way for us to increase education around some of the advanced diagnostic tools for brain injuries that can help correlate or distinguish brain-based disorders,” said Brett Green, vice president of CereLaw. “We also had the opportunity to meet with experts from various market segments and share best practices. The experiences and key learnings were invaluable.”

CereLaw is a division of CereScan, a functional brain diagnostics and data analytics company. The company has been involved in over 300 legal cases and has developed an unmatched success rate from cases in more than 30 states. With over 25 years of experience with brain injuries, CereScan’s team provides unparalleled expertise and support not found at other brain imaging facilities.

“The technology and team at CereScan has become a critical component to our TBI practice,” said Ronald W. Armstrong II, attorney at The Armstrong Firm, PLLC, San Antonio, Texas.  “Additionally, the quality of the results and professionalism exhibited by them is second to none.”

For more information about CereLaw’s brain forensic services please contact Brett Green at bgreen@cerescan.com or Lisa Teitelman at lteitelman@cerescan.com or call toll free at  (855) 838-2241. Connect with CereLaw on Twitter @CereLaw or online at https://www.cerelaw.com.